Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials and Equipment
2.2. Cell Culture
2.3. Experimental Animals
2.4. Melanoma Induction In Vivo and Treatment Regimens
2.5. Flow Cytometric Analysis of Tumors
2.6. Microscopic, Morphometric, and Stereological Analyses of the Tumors
2.6.1. Analysis of Melanin Pigmentation Level
2.6.2. Sudan Black B Staining
2.6.3. Immunofluorescence Detection of PCNA
2.6.4. Evaluation of the Mitotic Index
2.6.5. TUNEL Staining
2.6.6. Tumor Necrosis Volume Density
2.7. Histological Analysis of Liver and Kidneys
2.8. Statistical Analysis
3. Results
3.1. Therapeutic Effects of 3HFWC and HPL on Melanoma In Vivo
3.1.1. HFWC and HPL Affect Melanoma Growth In Vivo
3.1.2. HFWC and HPL Decrease Proliferation of Melanoma Cells In Vivo
3.1.3. HFWC and HPL Stimulate Differentiation and Senescence of Melanoma Cells In Vivo
3.1.4. Effects of 3HFWC and HPL on Melanoma-Associated Immune Cells In Vivo
3.2. Prophylactic and Combined Prophylactic-Therapeutic Effects of 3HFWC
3.3. Histological Assessment of 3HFWC and HPL Effects on Liver and Kidneys
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ott, P.A. Intralesional Cancer Immunotherapies. Hematol. Oncol. Clin. North Am. 2019, 33, 249–260. [Google Scholar] [CrossRef] [PubMed]
- Tarhini, A.; Atzinger, C.; Gupte-Singh, K.; Johnson, C.; Macahilig, C.; Rao, S. Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. J. Comp. Eff. Res. 2019, 8, 461–473. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today Lyon, France: International Agency for Research on Cancer. 2020. Available online: https://gco.iarc.fr/today (accessed on 18 October 2022).
- Cichorek, M.; Wachulska, M.; Stasiewicz, A.; Tyminska, A. Skin melanocytes: Biology and development. Postep. Dermatol. Alergol. 2013, 30, 30–41. [Google Scholar] [CrossRef]
- Ribas, A.; Hamid, O.; Daud, A.; Hodi, F.S.; Wolchok, J.D.; Kefford, R.; Joshua, A.M.; Patnaik, A.; Hwu, W.J.; Weber, J.S.; et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016, 315, 1600–1609. [Google Scholar] [CrossRef] [PubMed]
- El-Deiry, W.S.; Taylor, B.; Neal, J.W. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? Am. Soc. Clin. Oncol. Educ. Book 2017, 37, e8–e15. [Google Scholar] [CrossRef] [PubMed]
- Baghban, R.; Roshangar, L.; Jahanban-Esfahlan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Zare, P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020, 18, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tucci, M.; Passarelli, A.; Mannavola, F.; Felici, C.; Stucci, L.S.; Cives, M.; Silvestris, F. Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Front. Oncol. 2019, 9, 1148. [Google Scholar] [CrossRef] [Green Version]
- Liu, R.; Hu, R.; Zeng, Y.; Zhang, W.; Zhou, H.H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. EBioMedicine 2020, 51, 102602. [Google Scholar] [CrossRef] [Green Version]
- Huang, L.; Chen, H.; Xu, Y.; Chen, J.; Liu, Z.; Xu, Q. Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis. Cancer Med. 2020, 9, 8444–8456. [Google Scholar] [CrossRef]
- Leignadier, J.; Favre, S.; Luther, S.A.; Luescher, I.F. CD8 engineered cytotoxic T cells reprogram melanoma tumor environment. Oncoimmunology 2016, 5, e1086861. [Google Scholar] [CrossRef]
- Chung, J.S.; Tamura, K.; Cruz, P.D., Jr.; Ariizumi, K. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth. J. Investig. Dermatol. 2014, 134, 2784–2794. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ballas, Z.K.; Buchta, C.M.; Rosean, T.R.; Heusel, J.W.; Shey, M.R. Role of NK cell subsets in organ-specific murine melanoma metastasis. PLoS ONE 2013, 8, e65599. [Google Scholar] [CrossRef] [PubMed]
- Tham, M.; Tan, K.W.; Keeble, J.; Wang, X.; Hubert, S.; Barron, L.; Tan, N.S.; Kato, M.; Prevost-Blondel, A.; Angeli, V.; et al. Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget 2014, 5, 12027–12042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, L.; Guo, Y.; Liu, S.; Wang, H.; Zhu, J.; Ou, L.; Xu, X. Targeting regulatory T cells for immunotherapy in melanoma. Mol. Biomed. 2021, 2, 11. [Google Scholar] [CrossRef] [PubMed]
- Gao, X.; Sui, H.; Zhao, S.; Gao, X.; Su, Y.; Qu, P. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment. Front. Immunol. 2020, 11, 585214. [Google Scholar] [CrossRef]
- Sanlorenzo, M.; Vujic, I.; Posch, C.; Dajee, A.; Yen, A.; Kim, S.; Ashworth, M.; Rosenblum, M.D.; Algazi, A.; Osella-Abate, S.; et al. Melanoma immunotherapy. Cancer Biol. Ther. 2014, 15, 665–674. [Google Scholar] [CrossRef] [Green Version]
- Castano, A.P.; Mroz, P.; Hamblin, M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6, 535–545. [Google Scholar] [CrossRef] [Green Version]
- Mroz, P.; Szokalska, A.; Wu, M.X.; Hamblin, M.R. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS ONE 2010, 5, e15194. [Google Scholar] [CrossRef] [Green Version]
- Mroz, P.; Yaroslavsky, A.; Kharkwal, G.B.; Hamblin, M.R. Cell death pathways in photodynamic therapy of cancer. Cancers 2011, 3, 2516–2539. [Google Scholar] [CrossRef] [Green Version]
- Kwiatkowski, S.; Knap, B.; Przystupski, D.; Saczko, J.; Kedzierska, E.; Knap-Czop, K.; Kotlinska, J.; Michel, O.; Kotowski, K.; Kulbacka, J. Photodynamic therapy-mechanisms, photosensitizers and combinations. Biomed. Pharmacother. 2018, 106, 1098–1107. [Google Scholar] [CrossRef]
- Mai, T.T.; Yoo, S.W.; Park, S.; Kim, J.Y.; Choi, K.H.; Kim, C.; Kwon, S.Y.; Min, J.J.; Lee, C. In Vivo Quantitative Vasculature Segmentation and Assessment for Photodynamic Therapy Process Monitoring Using Photoacoustic Microscopy. Sensors 2021, 21, 1776. [Google Scholar] [CrossRef] [PubMed]
- Xu, P.; Liang, F. Nanomaterial-Based Tumor Photothermal Immunotherapy. Int. J. Nanomed. 2020, 15, 9159–9180. [Google Scholar] [CrossRef] [PubMed]
- Lee, E.H.; Lim, S.J.; Lee, M.K. Chitosan-coated liposomes to stabilize and enhance transdermal delivery of indocyanine green for photodynamic therapy of melanoma. Carbohydr. Polym. 2019, 224, 115143. [Google Scholar] [CrossRef] [PubMed]
- Sun, J.; Kormakov, S.; Liu, Y.; Huang, Y.; Wu, D.; Yang, Z. Recent Progress in Metal-Based Nanoparticles Mediated Photodynamic Therapy. Molecules 2018, 23, 1704. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.; Fan, T.; Xie, Z.; Zeng, Q.; Xue, P.; Zheng, T.; Chen, Y.; Luo, X.; Zhang, H. Advances in nanomaterials for photodynamic therapy applications: Status and challenges. Biomaterials 2020, 237, 119827. [Google Scholar] [CrossRef]
- Chen, A.; Grobmyer, S.R.; Krishna, V.B. Photothermal Response of Polyhydroxy Fullerenes. ACS Omega 2020, 5, 14444–14450. [Google Scholar] [CrossRef]
- Pickering, K.D.; Wiesner, M.R. Fullerol-sensitized production of reactive oxygen species in aqueous solution. Environ. Sci. Technol. 2005, 39, 1359–1365. [Google Scholar] [CrossRef]
- Kamat, J.P.; Devasagayam, T.P.; Priyadarsini, K.I.; Mohan, H. Reactive oxygen species mediated membrane damage induced by fullerene derivatives and its possible biological implications. Toxicology 2000, 155, 55–61. [Google Scholar] [CrossRef]
- Castro, E.; Hernandez Garcia, A.; Zavala, G.; Echegoyen, L. Fullerenes in Biology and Medicine. J. Mater. Chem. B 2017, 5, 6523–6535. [Google Scholar] [CrossRef]
- Mroz, P.; Tegos, G.P.; Gali, H.; Wharton, T.; Sarna, T.; Hamblin, M.R. Photodynamic therapy with fullerenes. Photochem. Photobiol. Sci. 2007, 6, 1139–1149. [Google Scholar] [CrossRef]
- Franskevych, D.; Palyvoda, K.; Petukhov, D.; Prylutska, S.; Grynyuk, I.; Schuetze, C.; Drobot, L.; Matyshevska, O.; Ritter, U. Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects. Nanoscale Res. Lett. 2017, 12, 40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tokuyama, H.; Yamago, S.; Nakamura, E.; Shiraki, T.; Sugiura, Y. Photoinduced biochemical activity of fullerene carboxylic acid. J. Am. Chem. Soc. 1993, 115, 7918–7919. [Google Scholar] [CrossRef]
- Koruga, D. Compositions comprising hyper harmonised hydroxyl modified fullerene substances. Cyprus, Patent WO 2021/110234 A1, 10 June 2021. [Google Scholar]
- Koruga, D. Composition of matter containing harmonized hydroxyl modified fullerene substance. USA, Patent US8058483B2, 15 November 2011. [Google Scholar]
- Miljkovic, S.; Jeftic, B.; Stankovic, I.; Stojiljkovic, N.; Koruga, D. Mechanisms of skin moisturization with hyperharmonized hydroxyl modified fullerene substance. J. Cosmet. Dermatol. 2021, 20, 3018–3025. [Google Scholar] [CrossRef] [PubMed]
- Jovanovic, T.; Koruga, D. Purification and Characterization of Fullerene Nanomaterials. Encycl. Nanosci. Nanotechnol. 2011, 21, 537–590. [Google Scholar]
- Lazovic, J.; Zopf, L.M.; Hren, J.; Gajdoš, M.; Slavkovic, M.; Jovic, Z.; Stankovic, I.; Matovic, V.; Koruga, D. Fullerene-Filtered Light Spectrum and Fullerenes Modulate Emotional and Pain Processing in Mice. Symmetry 2021, 13, 2004. [Google Scholar] [CrossRef]
- Markelic, M.; Draca, D.; Krajnovic, T.; Jovic, Z.; Vuksanovic, M.; Koruga, D.; Mijatovic, S.; Maksimovic-Ivanic, D. Combined Action of Hyper-Harmonized Hydroxylated Fullerene Water Complex and Hyperpolarized Light Leads to Melanoma Cell Reprogramming In Vitro. Nanomaterials 2022, 12, 1331. [Google Scholar] [CrossRef]
- Weibel, E.R.; Kistler, G.S.; Scherle, W.F. Practical stereological methods for morphometric cytology. J. Cell Biol. 1966, 30, 23–38. [Google Scholar] [CrossRef]
- Kotsafti, A.; Scarpa, M.; Castagliuolo, I.; Scarpa, M. Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion. Cancers 2020, 12, 1748. [Google Scholar] [CrossRef]
- Mijatovic, S.; Savic-Radojevic, A.; Pljesa-Ercegovac, M.; Simic, T.; Nicoletti, F.; Maksimovic-Ivanic, D. The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors. Antioxidants 2020, 9, 374. [Google Scholar] [CrossRef]
- Nardella, C.; Clohessy, J.G.; Alimonti, A.; Pandolfi, P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11, 503–511. [Google Scholar] [CrossRef]
- Wang, L.; Lankhorst, L.; Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 2022, 22, 340–355. [Google Scholar] [CrossRef] [PubMed]
- Hernandez-Segura, A.; Nehme, J.; Demaria, M. Hallmarks of Cellular Senescence. Trends Cell Biol. 2018, 28, 436–453. [Google Scholar] [CrossRef] [PubMed]
- Gorgoulis, V.; Adams, P.D.; Alimonti, A.; Bennett, D.C.; Bischof, O.; Bishop, C.; Campisi, J.; Collado, M.; Evangelou, K.; Ferbeyre, G.; et al. Cellular Senescence: Defining a Path Forward. Cell 2019, 179, 813–827. [Google Scholar] [CrossRef] [PubMed]
- Georgakopoulou, E.A.; Tsimaratou, K.; Evangelou, K.; Fernandez Marcos, P.J.; Zoumpourlis, V.; Trougakos, I.P.; Kletsas, D.; Bartek, J.; Serrano, M.; Gorgoulis, V.G. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging 2013, 5, 37–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coppé, J.-P.; Desprez, P.-Y.; Krtolica, A.; Campisi, J. The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression. Annu. Rev. Pathol. Mech. Dis. 2010, 5, 99–118. [Google Scholar] [CrossRef] [Green Version]
- Birch, J.; Gil, J. Senescence and the SASP: Many therapeutic avenues. Genes Dev. 2020, 34, 1565–1576. [Google Scholar] [CrossRef]
- Faget, D.V.; Ren, Q.; Stewart, S.A. Unmasking senescence: Context-dependent effects of SASP in cancer. Nat. Rev. Cancer 2019, 19, 439–453. [Google Scholar] [CrossRef]
- Ruscetti, M.; Morris, J.P.; Mezzadra, R.; Russell, J.; Leibold, J.; Romesser, P.B.; Simon, J.; Kulick, A.; Ho, Y.J.; Fennell, M.; et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 2020, 181, 424–441.e421. [Google Scholar] [CrossRef]
- Kang, T.W.; Yevsa, T.; Woller, N.; Hoenicke, L.; Wuestefeld, T.; Dauch, D.; Hohmeyer, A.; Gereke, M.; Rudalska, R.; Potapova, A.; et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479, 547–551. [Google Scholar] [CrossRef]
- Ruscetti, M.; Leibold, J.; Bott, M.J.; Fennell, M.; Kulick, A.; Salgado, N.R.; Chen, C.C.; Ho, Y.J.; Sanchez-Rivera, F.J.; Feucht, J.; et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 2018, 362, 1416–1422. [Google Scholar] [CrossRef] [Green Version]
- Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445, 851–857. [Google Scholar] [CrossRef] [PubMed]
- Michaloglou, C.; Vredeveld, L.C.; Soengas, M.S.; Denoyelle, C.; Kuilman, T.; van der Horst, C.M.; Majoor, D.M.; Shay, J.W.; Mooi, W.J.; Peeper, D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436, 720–724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paskas, S.; Krajnovic, T.; Basile, M.S.; Dunderovic, D.; Cavalli, E.; Mangano, K.; Mammana, S.; Al-Abed, Y.; Nicoletti, F.; Mijatovic, S.; et al. Senescence as a main mechanism of Ritonavir and Ritonavir-NO action against melanoma. Mol. Carcinog. 2019, 58, 1362–1375. [Google Scholar] [CrossRef] [PubMed]
- Bandyopadhyay, D.; Medrano, E.E. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1. Ann. N. Y. Acad. Sci. 2000, 908, 71–84. [Google Scholar] [CrossRef] [PubMed]
- Raposo, G.; Marks, M.S. Melanosomes--dark organelles enlighten endosomal membrane transport. Nat. Rev. Mol. Cell Biol. 2007, 8, 786–797. [Google Scholar] [CrossRef] [Green Version]
- Chen, K.G.; Leapman, R.D.; Zhang, G.; Lai, B.; Valencia, J.C.; Cardarelli, C.O.; Vieira, W.D.; Hearing, V.J.; Gottesman, M.M. Influence of melanosome dynamics on melanoma drug sensitivity. J. Natl. Cancer Inst. 2009, 101, 1259–1271. [Google Scholar] [CrossRef] [Green Version]
- Sarna, M.; Krzykawska-Serda, M.; Jakubowska, M.; Zadlo, A.; Urbanska, K. Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion. Sci. Rep. 2019, 9, 9280. [Google Scholar] [CrossRef] [Green Version]
- Zimmerman, M.A.; Huang, Q.; Li, F.; Liu, X.; Li, C.Y. Cell death-stimulated cell proliferation: A tissue regeneration mechanism usurped by tumors during radiotherapy. Semin. Radiat. Oncol. 2013, 23, 288–295. [Google Scholar] [CrossRef] [Green Version]
- Ichim, G.; Tait, S.W. A fate worse than death: Apoptosis as an oncogenic process. Nat. Rev. Cancer 2016, 16, 539–548. [Google Scholar] [CrossRef] [Green Version]
- Mijatovic, S.; Bramanti, A.; Nicoletti, F.; Fagone, P.; Kaluderovic, G.N.; Maksimovic-Ivanic, D. Naturally occurring compounds in differentiation based therapy of cancer. Biotechnol. Adv. 2018, 36, 1622–1632. [Google Scholar] [CrossRef] [Green Version]
- O’Donnell, J.S.; Teng, M.W.L.; Smyth, M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019, 16, 151–167. [Google Scholar] [CrossRef]
- Bonaventura, P.; Shekarian, T.; Alcazer, V.; Valladeau-Guilemond, J.; Valsesia-Wittmann, S.; Amigorena, S.; Caux, C.; Depil, S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol. 2019, 10, 168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duan, Q.; Zhang, H.; Zheng, J.; Zhang, L. Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends Cancer 2020, 6, 605–618. [Google Scholar] [CrossRef] [PubMed]
- Maleki Vareki, S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 2018, 6, 157. [Google Scholar] [CrossRef]
- Huff, W.X.; Kwon, J.H.; Henriquez, M.; Fetcko, K.; Dey, M. The Evolving Role of CD8(+)CD28(−) Immunosenescent T Cells in Cancer Immunology. Int. J. Mol. Sci. 2019, 20, 2810. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galli, F.; Aguilera, J.V.; Palermo, B.; Markovic, S.N.; Nisticò, P.; Signore, A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J. Exp. Clin. Cancer Res. 2020, 39, 89. [Google Scholar] [CrossRef]
- Labani-Motlagh, A.; Ashja-Mahdavi, M.; Loskog, A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front. Immunol. 2020, 11, 940. [Google Scholar] [CrossRef]
- Marín, I.; Boix, O.; García, A.; Sirois, I.; Caballe, A.; Zarzuela, E.; Ruano, I.; Stephan-Otto Attolini, C.; Prats, N.; López-Domínguez, J.A.; et al. Induction of senescence renders cancer cells highly immunogenic. bioRxiv 2022. [Google Scholar] [CrossRef]
- Dong, H.; Hu, L.; Li, W.; Shi, M.; He, L.; Wang, C.; Hu, Y.; Wang, H.; Wen, C.; Liu, H.; et al. Pyrimethamine inhibits cell growth by inducing cell senescence and boosting CD8+ T-cell mediated cytotoxicity in colorectal cancer. Mol. Biol. Rep. 2022, 49, 4281–4292. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Markelić, M.; Mojić, M.; Bovan, D.; Jelača, S.; Jović, Z.; Purić, M.; Koruga, D.; Mijatović, S.; Maksimović-Ivanić, D. Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo. Nanomaterials 2023, 13, 372. https://doi.org/10.3390/nano13030372
Markelić M, Mojić M, Bovan D, Jelača S, Jović Z, Purić M, Koruga D, Mijatović S, Maksimović-Ivanić D. Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo. Nanomaterials. 2023; 13(3):372. https://doi.org/10.3390/nano13030372
Chicago/Turabian StyleMarkelić, Milica, Marija Mojić, Dijana Bovan, Sanja Jelača, Zorana Jović, Milica Purić, Djuro Koruga, Sanja Mijatović, and Danijela Maksimović-Ivanić. 2023. "Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo" Nanomaterials 13, no. 3: 372. https://doi.org/10.3390/nano13030372
APA StyleMarkelić, M., Mojić, M., Bovan, D., Jelača, S., Jović, Z., Purić, M., Koruga, D., Mijatović, S., & Maksimović-Ivanić, D. (2023). Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo. Nanomaterials, 13(3), 372. https://doi.org/10.3390/nano13030372